Intracarotid VP-16 in malignant brain tumors

Lynn G. Feun, Ya Yen Lee, Wai Kwan Alfred Yung, Niramol Savaraj, Sidney Wallace

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Twenty-eight patients with malignant brain tumors (16 with primary brain tumors and 12 with brain metastases) progressing after cranial irradiation with or without chemotherapy received varying doses of intracarotid VP-16. Courses of therapy were repeated every 4 weeks along with computerized axial tomography scan and neurologic examination. Of 15 evaluable patients with primary malignant brain tumors, 1 responded to therapy and 5 had no immediate tumor progression for 2-10 months. None of 12 evaluable patients with brain metastases responded to intracarotid VP-16 although 5 had no immediate tumor progression from 1-4 months. Side effects of treatment were uncommon. Using this route of administration, intracarotid VP-16 does not appear to increase response rates in patients with primary malignant brain tumors, compared with results reported for intravenous VP-16.

Original languageEnglish (US)
Pages (from-to)397-401
Number of pages5
JournalJournal of neuro-oncology
Issue number4
StatePublished - Dec 1987


  • brain tumors
  • intracarotid
  • VP-16

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Intracarotid VP-16 in malignant brain tumors'. Together they form a unique fingerprint.

Cite this